↓ Skip to main content

PLOS

Pterostilbene Acts through Metastasis-Associated Protein 1 to Inhibit Tumor Growth, Progression and Metastasis in Prostate Cancer

Overview of attention for article published in PLOS ONE, March 2013
Altmetric Badge

Mentioned by

news
10 news outlets
twitter
2 X users
patent
1 patent
facebook
2 Facebook pages

Citations

dimensions_citation
88 Dimensions

Readers on

mendeley
50 Mendeley
Title
Pterostilbene Acts through Metastasis-Associated Protein 1 to Inhibit Tumor Growth, Progression and Metastasis in Prostate Cancer
Published in
PLOS ONE, March 2013
DOI 10.1371/journal.pone.0057542
Pubmed ID
Authors

Kun Li, Steven J. Dias, Agnes M. Rimando, Swati Dhar, Cassia S. Mizuno, Alan D. Penman, Jack R. Lewin, Anait S. Levenson

Abstract

The development of natural product agents with targeted strategies holds promise for enhanced anticancer therapy with reduced drug-associated side effects. Resveratrol found in red wine, has anticancer activity in various tumor types. We reported earlier on a new molecular target of resveratrol, the metastasis-associated protein 1 (MTA1), which is a part of nucleosome remodeling and deacetylation (NuRD) co-repressor complex that mediates gene silencing. We identified resveratrol as a regulator of MTA1/NuRD complex and re-activator of p53 acetylation in prostate cancer (PCa). In the current study, we addressed whether resveratrol analogues also possess the ability to inhibit MTA1 and to reverse p53 deacetylation. We demonstrated that pterostilbene (PTER), found in blueberries, had greater increase in MTA1-mediated p53 acetylation, confirming superior potency over resveratrol as dietary epigenetic agent. In orthotopic PCa xenografts, resveratrol and PTER significantly inhibited tumor growth, progression, local invasion and spontaneous metastasis. Furthermore, MTA1-knockdown sensitized cells to these agents resulting in additional reduction of tumor progression and metastasis. The reduction was dependent on MTA1 signaling showing increased p53 acetylation, higher apoptotic index and less angiogenesis in vivo in all xenografts treated with the compounds, and particularly with PTER. Altogether, our results indicate MTA1 as a major contributor in prostate tumor malignant progression, and support the use of strategies targeting MTA1. Our strong pre-clinical data indicate PTER as a potent, selective and pharmacologically safe natural product that may be tested in advanced PCa.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Portugal 1 2%
Unknown 49 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 10 20%
Student > Ph. D. Student 9 18%
Researcher 9 18%
Student > Master 6 12%
Other 4 8%
Other 2 4%
Unknown 10 20%
Readers by discipline Count As %
Agricultural and Biological Sciences 16 32%
Medicine and Dentistry 5 10%
Chemistry 4 8%
Biochemistry, Genetics and Molecular Biology 3 6%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Other 6 12%
Unknown 13 26%